Key result
Isradipine reduces MAP and increases renal plasma flow ~16% vs placebo without altering GFR.
Why the study?
The effects of long-term isradipine administration on renal hemodynamics and sodium metabolism in patients with mild-to-moderate hypertension were not fully characterized.
Does isradipine improve renal hemodynamics and function in patients with mild-to-moderate hypertension?
Comparison
Isradipine 2.5 mg twice daily vs placebo
Design
Double-blind placebo-controlled study
Follow-up
3 months
Authors
Loading...
Supports isradipine for hypertension with renal hemodynamic benefits; extends evidence on dihydropyridine effects in an RCT.
RCT (n=10)
Double-blind
Does isradipine improve renal hemodynamics and function in patients with mild-to-moderate hypertension?
Low-dose isradipine effectively controls blood pressure while exerting a protective effect on renal hemodynamics and maintaining stable natriuresis.
Francischetti et al. (1992) conducted an RCT in Mild-to-moderate hypertension (n=10). Isradipine vs. Placebo was evaluated on Renal hemodynamics and function. Isradipine monotherapy significantly reduced mean arterial pressure and increased effective renal plasma flow (+16%) while leaving glomerular filtration rate virtually unchanged (-8.7 ml/min).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: